Proteoglycan 4 Mechanism the Effectiveness of Pulmaonry Recovery in COPD Patients

May 5, 2016 updated by: Shu-Chuan Ho, Taipei Medical University

Studies in Pulmonary Inflammation and the Effectiveness of Pulmonary Recovery in COPD Patients:the Mechanism of Proteoglycan 4

The investigators previous research has demonstrated that proteoglycan 4 (PRG4) may be a biomarker for identification of severity in COPD. PRG4 was more sensitive and specific than CRP for confirming COPD severity and acute exacerbation frequency. It was related to the 1-year force vital capacity decline in COPD patients. The past study found that Prg4 is an immunomodulatory factor regulating parathyroid hormone actions on hematopoietic cells in mice. Previous report showed that voluntary wheel running and fluid flow shear stress that promote the expression of the Prg4 and association with pulmonary inflammation. COPD patients are characterized by a progressive decrease of lung function that is associated with increased in the airway and systemic inflammation. Pulmonary recovery (PR) is able to decrease acute exacerbation, maintain pulmonary function, increase exercise tolerance and improve quality of life in COPD patients, but it is unknown the mechanism of PRG4. The current study aimed to study in the pulmonary inflammation and the effectiveness of pulmonary recovery in COPD Patients:The mechanism of PRG 4.

Study Overview

Detailed Description

The investigators previous research has demonstrated that proteoglycan 4 (PRG4) may be a biomarker for identification of severity in COPD. PRG4 was more sensitive and specific than CRP for confirming COPD severity and acute exacerbation frequency. It was related to the 1-year force vital capacity decline in COPD patients. The past study found that Prg4 is an immunomodulatory factor regulating parathyroid hormone actions on hematopoietic cells in mice. Previous report showed that voluntary wheel running and fluid flow shear stress that promote the expression of the Prg4 and association with pulmonary inflammation. COPD patients are characterized by a progressive decrease of lung function that is associated with increased in the airway and systemic inflammation. Pulmonary recovery (PR) is able to decrease acute exacerbation, maintain pulmonary function, increase exercise tolerance and improve quality of life in COPD patients, but it is unknown the mechanism of PRG4. The current study aimed to study in the pulmonary inflammation and the effectiveness of pulmonary recovery in COPD Patients:The mechanism of PRG 4.

  1. Proteoglycan 4 is correlated with pulmonary inflammation and decline of pulmonary function in the different phenotype of COPD.

    1-1 Classification of characteristic、the severity of disease、pulmonary functional test、exercise capacity and blood sample collection for routine analysis.

    1-2 Human blood bio-bank and molecular analysis: PRG4、IL-6、IL-8、TNFα、CRP& IL-10.

    1-3 To investigate whether daily physical activity、hypoxia and hyperinflation were associated with airway inflammation and PRG4 in COPD patients.

  2. The mechanism of PRG 4 in the effectiveness of PR on the AECOPD. 2-1 The PR program: The combination effect of negative pressure ventilation and exercise training program on acute exacerbation of COPD (AECOPD).

    2-2 To examine the efficacy of PR on cytokines and PRG4 protein. 2-3 Correlation between PR effects and PRG4:PR is correlation with PRG4、clinical progression、exercise tolerance、PFT change and SpO2 during exercise.

  3. In vitro cell culture research models 3-1 Pulmonary inflammatory model establishment:Human primary epithelium cell culture and Beas-2B for IL-1β、TNFα、LPS、IL-10 and H2O2 effects.

    3-2 Purification of peripheral blood monocyte cells:Primary culture to evaluate pulmonary inflammation and treatment effects.

    3-3 Hypoxia experiments:To test whether hypoxia induces regulation of PRG4 protein or different cytokines in epithelial cells.

    3-4 Inhibit PRG4:To prove the mechanism of PRG4 under the hypoxia model by PRG4 siRNA。

  4. In vivo animal research models 4-1 Smoke-COPD mice models establishment: 4-2 To determinate the effects of exercise training in COPD mine. 4-3 To investigate on PRG4 protein in pulmonary inflammation and the effectiveness of exercise training in the tissue and serum of mice.

Study Type

Interventional

Enrollment (Anticipated)

90

Phase

  • Not Applicable

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

40 years to 85 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Hospitalized patients with acute exacerbation of COPD

    1. GOLD diagnostic criteria based on the COPD, the use of inhaled bronchodilators: the first second forced expiratory volume (FEV1.0) / forced vital capacity (FVC) <70%.
    2. Age ≧ 40 and ≦ 80 years old, is currently not accepting any research project.
    3. Physician assess the patient is currently in stable condition vital signs, complain dyspnea of exercise, consult RT for pulmonary rehabilitation.
    4. The purpose of this study by researchers explain, the researchers agreed to participate in this.

Stable COPD outpatients

  1. GOLD diagnostic criteria based on the COPD, the use of inhaled bronchodilators: the first second forced expiratory volume (FEV1.0) / forced vital capacity (FVC) <70%.
  2. Age ≧ 40 and ≦ 80 years old, is currently not accepting any research project.
  3. The purpose of this study by researchers explain, the researchers agreed to participate in this.

Exclusion Criteria:

  • Hospitalized patients with acute exacerbation of COPD

    1. Unstable vital signs: blood pressure <90 mm Hg, blood oxygen levels (SpO2) at Tx under still <85%.
    2. Associated with neuromuscular function disorders such as hemiplegia or no independent walking function.
    3. Have been diagnosed with severe mental disorders, such as dementia or or unable to cooperating people.

Stable COPD outpatients

  1. Over the past three months there have been acute infection or are in a state of acute attacks.
  2. Associated with neuromuscular function disorders such as hemiplegia or no independent walking function.
  3. Have been diagnosed with severe mental disorders, such as dementia or unable to cooperating people

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: HEALTH_SERVICES_RESEARCH
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: DOUBLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Pulmonary recovery on the AECOPD
Study in the pulmonary inflammation and the effectiveness of pulmonary recovery in AECOPD Patients
The combination effect of negative pressure ventilation, limb muscle exercise training program and fibit monitor on acute exacerbation of AECOPD. To investigate the daily physical activity in routine care patients with after AECOPD and stable stage.
Other Names:
  • Ergometer for limb muscle training
  • Negative pressure ventilator
  • Fibit monitor
To investigate whether daily physical activity、hypoxia and hyperinflation were associated with airway inflammation and PRG4 in Routine care patients wtih AECOPD and stable stage.
Other Names:
  • Fibit monitor
  • Physical daily activity
To investigate whether daily physical activity、hypoxia and hyperinflation were associated with airway inflammation and PRG4 in Non-Pulmanary recovery patients wtih stable COPD.
Other Names:
  • Fibit monitor
  • Physical daily activity
OTHER: Routine care on the AECOPD
Study in the pulmonary inflammation and the effectiveness of pulmonary recovery in AECOPD Patients
To investigate whether daily physical activity、hypoxia and hyperinflation were associated with airway inflammation and PRG4 in Routine care patients wtih AECOPD and stable stage.
Other Names:
  • Fibit monitor
  • Physical daily activity
To investigate whether daily physical activity、hypoxia and hyperinflation were associated with airway inflammation and PRG4 in Non-Pulmanary recovery patients wtih stable COPD.
Other Names:
  • Fibit monitor
  • Physical daily activity
OTHER: Routine care on the stable COPD
Study in the pulmonary inflammation and the effectiveness of pulmonary recovery in stabel COPD Patients
To investigate whether daily physical activity、hypoxia and hyperinflation were associated with airway inflammation and PRG4 in Non-Pulmanary recovery patients wtih stable COPD.
Other Names:
  • Fibit monitor
  • Physical daily activity

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The systemic inflamation biomakers
Time Frame: 0~12 months
Measured the proteaglycan4、IL-6、IL-8、TNFα、CRP& IL-10 from the supernatant with COPD patients
0~12 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Exercise capacity
Time Frame: 0~12 months
Six-minute walking distance and lung
0~12 months
The correlaton with the exercise capacity and systemic inflammationcytokines
Time Frame: 0~12 months
volumePulmonary recovery is correlation with PRG4、clinical progression、exercise tolerance、PFT change and SpO2 during exercise
0~12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Shu-Chuan Ho, School of Respiratory Therapy, College of Medicine, Taipei Medical University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

May 1, 2016

Primary Completion (ANTICIPATED)

February 1, 2019

Study Completion (ANTICIPATED)

February 1, 2019

Study Registration Dates

First Submitted

May 1, 2016

First Submitted That Met QC Criteria

May 3, 2016

First Posted (ESTIMATE)

May 6, 2016

Study Record Updates

Last Update Posted (ESTIMATE)

May 9, 2016

Last Update Submitted That Met QC Criteria

May 5, 2016

Last Verified

May 1, 2016

More Information

Terms related to this study

Other Study ID Numbers

  • TMU-JIRB Ho1.2/20160212

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on COPD

Clinical Trials on Pulmonary recovery on the AECOPD

3
Subscribe